Literature DB >> 19031085

Can CD10 be used as a diagnostic marker in thyroid pathology?

Gülçin Yegen1, Mehmet Akif Demir, Yeşim Ertan, Olcay Ak Nalbant, Müge Tunçyürek.   

Abstract

CD10-common acute lymphoblastic leukemia antigen is a membrane-bound zinc metalloproteinase that is expressed by different hematopoietic cell types at unique stages of lymphoid and myeloid differentiation. It was reported to be expressed in various nonlymphoid cells and tissue, as well as in various types of neoplasms. Recently, it has been found to be useful in the differential diagnosis of benign and malignant follicular-patterned lesions of the thyroid. In the present study, we evaluated the staining pattern of CD10 in various thyroid lesions, including 14 benign and 61 malignant cases, as well as in adjacent thyroid tissue. CD10 was negative in normal thyroid tissue, adenomatous nodules, minimally invasive follicular carcinoma, and well-differentiated carcinoma. It was expressed in nine of 14 (64.2%) conventional papillary carcinomas, four of 24 (16.6%) follicular variant of papillary carcinomas, three of six (50%) papillary microcarcinomas, one of nine (11.1%) widely invasive follicular carcinomas, and three of ten (30%) follicular adenomas. In contrast to results of previous studies, CD10 is not useful in the classification of thyroid follicular lesions as benign or malignant, but it shows strong positivity in conventional papillary carcinoma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19031085     DOI: 10.1007/s00428-008-0698-2

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  17 in total

Review 1.  Follicular-patterned lesions of the thyroid: the bane of the pathologist.

Authors:  Zubair W Baloch; Virginia A Livolsi
Journal:  Am J Clin Pathol       Date:  2002-01       Impact factor: 2.493

2.  Guest Editorial: Two Proposals Regarding the Terminology of Thyroid Tumors.

Authors:  E. Dillwyn Williams
Journal:  Int J Surg Pathol       Date:  2000-07       Impact factor: 1.271

3.  Interobserver and intraobserver reproducibility in the histopathology of follicular thyroid carcinoma.

Authors:  Brigitte Franc; Pauline de la Salmonière; Françoise Lange; Catherine Hoang; Albert Louvel; Anne de Roquancourt; Françoise Vildé; Gilles Hejblum; Sylvie Chevret; Claude Chastang
Journal:  Hum Pathol       Date:  2003-11       Impact factor: 3.466

4.  Expression of the common acute lymphoblastic leukemia antigen (CD10) in mesenchymal tumors.

Authors:  G Mechtersheimer; P Möller
Journal:  Am J Pathol       Date:  1989-05       Impact factor: 4.307

5.  Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules.

Authors:  M F Beesley; K M McLaren
Journal:  Histopathology       Date:  2002-09       Impact factor: 5.087

6.  Role of p53, CD44V6 and CD57 in differentiating between benign and malignant follicular neoplasms of the thyroid.

Authors:  Aejaz Nasir; Edison Catalano; Stephanie Calafati; Alan Cantor; Hans E Kaiser; Domenico Coppola
Journal:  In Vivo       Date:  2004 Mar-Apr       Impact factor: 2.155

7.  CD10 expression is useful in the diagnosis of follicular carcinoma and follicular variant of papillary thyroid carcinoma.

Authors:  Chisato Tomoda; Ryoji Kushima; Eiji Takeuti; Ken-Ichi Mukaisho; Takanori Hattori; Hiroya Kitano
Journal:  Thyroid       Date:  2003-03       Impact factor: 6.568

8.  Specific pattern of RAS oncogene mutations in follicular thyroid tumors.

Authors:  V Vasko; M Ferrand; J Di Cristofaro; P Carayon; J F Henry; C de Micco
Journal:  J Clin Endocrinol Metab       Date:  2003-06       Impact factor: 5.958

9.  Follicular neoplasms of the thyroid. A study of 44 cases followed for a minimum of 10 years, with emphasis on differential diagnosis.

Authors:  H L Evans
Journal:  Cancer       Date:  1984-08-01       Impact factor: 6.860

10.  Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma.

Authors:  Ricardo V Lloyd; Lori A Erickson; Mary B Casey; King Y Lam; Christine M Lohse; Sylvia L Asa; John K C Chan; Ronald A DeLellis; H Ruben Harach; Kennichi Kakudo; Virginia A LiVolsi; Juan Rosai; Thomas J Sebo; Manuel Sobrinho-Simoes; Bruce M Wenig; Marick E Lae
Journal:  Am J Surg Pathol       Date:  2004-10       Impact factor: 6.394

View more
  5 in total

1.  An Unusual Solitary Thyroid Nodule with Bloody Follicles: Metastatic Renal Cell Carcinoma Within an Infiltrative Follicular Variant Papillary Carcinoma.

Authors:  Mehmet Kefeli; Ozgur Mete
Journal:  Endocr Pathol       Date:  2016-06       Impact factor: 3.943

Review 2.  Metastatic Clear Cell Renal Cell Carcinoma Involving the Thyroid Gland: A Clinicopathologic Study of 17 Patients.

Authors:  Jaylou M Velez Torres; Laurence M Briski; Ernesto Martinez Duarte; Peter M Sadow; Darcy A Kerr; Oleksandr N Kryvenko
Journal:  Int J Surg Pathol       Date:  2022-03-07       Impact factor: 1.358

3.  Advances in cellular therapy for the treatment of thyroid cancer.

Authors:  Claudia Papewalis; Margret Ehlers; Matthias Schott
Journal:  J Oncol       Date:  2010-06-29       Impact factor: 4.375

4.  Diagnostic value of CD-10 marker in differentiating of papillary thyroid carcinoma from benign thyroid lesions.

Authors:  Mojgan Mokhtari; Farahnaz Ameri
Journal:  Adv Biomed Res       Date:  2014-10-20

Review 5.  Role of B Cell Development Marker CD10 in Cancer Progression and Prognosis.

Authors:  Deepshikha Mishra; Sunita Singh; Gopeshwar Narayan
Journal:  Mol Biol Int       Date:  2016-11-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.